In both cases, VP reduced tumor growth and cancer cell proliferation when administered daily (Fig. 5f–k), suggesting that YAP1 is an attractive therapeutic target in human HNSCC and likely other human malignancies. This evidence concerns the gene YAP1 and neoplasm.